POSC:
Sorry to spam... .
If you are interested in another play over the next 4-6 weeks here is an interesting one. The news is coming soon.
POSC: A small radiopharmaceutical compoany
They are about to receive funding for a huge project that will make the company a big player in the radiopharma market.
The costs for the project, including: equipment, building, land, working capital and contingencies, is approximately $60 million dollars.
The total amount of funding that Positron is seeking is approximately $91 million; $36 million from capital lease and/or construction financing (debt financing) and $6.7 million from Tax Increment Financing Bonds, which are conditionally secured. If Disaster Area Bonds are available, in the amount applied for ($37.5 million).
Positron may replace all or a portion of the capital lease and/or construction financing by raising $49 million in private funding from the sale of 49% of its capital stock; $26 million of which is intended to be loaned to Positron Corporation in the form of a secured note from a newly formed subsidiary that the company has formed called Positron Isotopes.
This news should be coming in the next few weeks. We have spoken to the CEO and have confirmed that this is completely NON dilutive financing. Market cap is $20MM. So this funding makes the company worth much more than current value.
POSC is likely going to receive $49 million in private money.
> POsitron is in the process of increasing its authorized shares so to fully reflect its capitalization. Increasing the authorized shares will have no effect on the number of outstanding shares. Capital necessary for the execution of Positron's expansion plans will come in part from project financing which we anticipate no dilution to Positron's shareholders.
>
> The financing of this $91 million project is a key initiative that represents tremendous present and future value. The proposed 70 MeV cyclotron is a significant component of our long term strategy and further strengthens the macro business model and our position in the marketplace. This added value and capital will enables us to execute our plan; selling a complete cardiac solution is the future and a powerful advantage.
>
> We have a number of significant strategic opportunities that offer growth, security and a competitive edge throughout the value chain. It has been the Company's focus to build on a solid foundation of core components and bring them all together through innovative financial offerings. The industry is looking for complete solutions and the security of supply for the long term. Positron's plan is to deliver just that.
